Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases

Abstract

Background: Inhaled long-acting antimuscarinic agents are first line bronchodilator options for treatment of stable moderate-to-severe COPD patients (pts). In the GLOW2 trial glycopyrronium (GLY) demonstrated faster onset of action vs open-label tiotropium (TIO), with greater levels of bronchodilation in the initial 4 h following administration.Aim: To show superiority of GLY (50 mg) compared to TIO (18 mg)in FEV₁AUC_0-4h after first dose in symptomatic patients with moderate to severe COPD. Secondary efficacy objectives included comparisons of symptoms on Day 1 and 28.Methods: This was a prospective multi-centre, randomized, blinded, two-period cross-over study; each treatment lasted 28 days, with 14-19 days wash-out between treatments.Results: Of 124 pts randomized, 70.2% were male, mean age was 65.7 y. Least square means (95% CI) FEV₁AUC_0-4h after first treatment dose was 1.74 (1.71, 1.77)L for GLY and 1.71 (1.68, 1.74)L for TIO; difference 0.030 (0.004, 0.056)L, p=0.025, in favour of GLY. A numerical difference in improvement of morning COPD symptoms was observed in favour of GLY [mean (SD) -6.9 (6.6) vs -5.9 (6.6) for GLY and TIO respectively (p=0.144)]. GLY was also numerically better in FEV₁AUC_0-4h when compared to TIO on Day 28. The Day 28 PRO-morning COPD symptom score was not different between treatments. There were no differences in the safety profile between GLY and TIO.Conclusions: GLY demonstrated superiority of GLY compared to TIO in terms of FEV₁AUC_0-4h after the first dose of treatment, further supporting better bronchodilation with GLY during the 4 h following administration.


Rating:

Share or cite this content

Citations should be made in the following way:
Jose M. Marin Trigo (Zaragoza, Spain), Jose Mª Marin, Andreas Clemens, Ricard Casamor, Walter Castellani, Lennart Schaper, Dinesh Saralaya, Anthony Gunstone, Konstantinos Kostikas, Maryam Aalamian-Mattheis, Kai Beeh. Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study. Eur Respir J 2015; 46: Suppl. 59, 1014

Member's Comments

No comment yet.

Related content which might interest you: Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Once-daily QVA149 improves symptom scores in patients with COPD Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013